Antibody-drug conjugate · Cytotoxic, directed at CD19 · developed by Adc Therapeutics Sa
Loncastuximab tesirine is an antibody-drug conjugate targeting CD19, consisting of an anti-CD19 monoclonal antibody conjugated to SG3199, a pyrrolobenzodiazepine dimer. Upon binding and internalization, the cytotoxic payload is released and forms DNA interstrand crosslinks, inducing cell death.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jun 12, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05991388 | Phase 2/3 | B-cell Non Hodgkin Lymphoma | Recruiting | ADCT |
| NCT05296070 | Phase 2 | Marginal Zone Lymphoma | Recruiting | ADCT |
| NCT06607549 | Phase 1 | Central Nervous System Lymphoma | Recruiting | ADCT |
| NCT05971251 | Phase 1 | Chronic Lymphocytic Leukemia | Active not recruiting | ADCT |
| NCT03685344 | Phase 1 | Diffuse Large B-Cell Lymphoma | Terminated | ADCT |
| NCT02669264 | Phase 1 | Acute Lymphoblastic Leukemia | Terminated | ADCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
B-cell Non Hodgkin LymphomaCentral Nervous System LymphomaChronic Lymphocytic LeukemiaMarginal Zone LymphomaAcute Lymphoblastic LeukemiaDiffuse Large B-Cell LymphomaFollicular LymphomaMantle Cell Lymphoma
Updated Oct 3, 2026. Something wrong or missing? Report it on the ADCT page.
See ADCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ADCT catalysts and pipeline →